Ak­ili out­lines adult AD­HD da­ta for pre­scrip­tion video game; Medtech start­up to go pub­lic via SPAC

The dig­i­tal med­i­cine biotech Ak­ili In­ter­ac­tive re­vealed topline re­sults from a tri­al for its video game-like dig­i­tal ther­a­py En­deav­or­Rx, al­so known as AKL-TO1, in adults with AD­HD, with some pos­i­tive re­sults.

On Wednes­day, the biotech said the game pro­duced a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in at­ten­tion func­tion­ing from pa­tients af­ter six weeks of treat­ment com­pared to place­bo. Im­prove­ments were al­so not­ed in sev­er­al sec­ondary out­comes re­lat­ed to as­sess­ments of AD­HD-re­lat­ed symp­toms and qual­i­ty of life met­rics. Ak­ili re­port­ed no se­ri­ous side ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.